MySugr offers a handful of apps, but its flagship is called Diabetes Logbook, which is designed for people with type 1 or type 2 diabetes and includes logging, graphing, analysis, and Apple Health integration. If users sign up for a month-to-month or annual subscription, pro features include additional challenges, automatic blood glucose logging from connected devices, reminders, and more report formats. Its Logbook app is registered as a class 1 device with the FDA and has similar status in Europe. MySugr Logbook has more than 600,000 registered users, according to the company.
Users that own Roche’s Accu-Chek Connect meter will be able to automatically sync blood glucose data to mySugr. These users will also have access to the pro version of the mySugr app. This integrated offering will be available first in Germany and Austria, but will eventually launch in the US and other markets, according to the company.
"This co-operation will bring true innovation to our customers," Marcel Gmuender, global head of Roche Diabetes Care, said in a statement. "Digital diabetes care solutions have proven to help manage diabetes-related data more comprehensively. This makes data more meaningful and can ultimately lead to better therapy outcomes.”
In March 2015, mySugr raised $4.8 million from Roche Ventures and iSeed Ventures. Existing investor XLHealth also contributed to the round. The company said at the time that this funding would help mySugr scale up its user base in the US and other other countries.
A few months later, Roche quietly launched its Accu-Chek Connect app, a diabetes management app that contains, among other things, a prescription insulin bolus calculator called Bolus Advisor. It received FDA clearance for the Android version of the app in mid-March and finally received clearance for the iOS version in early June, using the Android clearance as the predicate device.